Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06174935
Study type Interventional
Source Prism Vision Group
Contact Jeanette Du, MD
Phone 844-749-3627
Email JDu@rgw.com
Status Not yet recruiting
Phase Phase 2
Start date January 1, 2024
Completion date June 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT01970267 - Clear Vision Study N/A